Skip to main content

Did You Know? 2026 Dyslipidemia Guidelines

ACC/AHA/Multisociety Guidelines on the Management of Dyslipidemia

Replaces the 2018 AHA/ACC/Multisociety Guideline on the Management of Blood Cholesterol.

Primary Prevention: What’s new?

  • The PREVENT-ASCVD equation is endorsed over the Pooled Cohort Equations (PCE) for estimating ASCVD (atherosclerotic cardiovascular disease) risk in adults aged 30-79 years, without ASCVD or subclinical atherosclerosis. The 10- and 30- year risk assessment helps to guide lipid-lowering therapy in primary prevention: https://professional.heart.org/en/guidelines-and-statements/prevent-calculator
  • TREATMENT GOALS ARE BACK!
    • Clinical trials have shown that greater LDL reduction leads to fewer cardiovascular events and additional protection against MI and stroke for those at high ASCVD risk.
    • There are new risk thresholds for initiating and intensifying lipid-lowering therapy. Percentage reductions in LDL-C are typically used to guide initial therapy intensity, while absolute LDL-C and non-HDL-C thresholds are used to guide treatment intensification.
    • Lifestyle interventions should be encouraged in all patients.

Adults 30-79 years of age with LDL-C 70-189 mg/dL:

10-year ASCVD riskTreatmentGoals
Low risk: <3%Lifestyle interventions.

If patient is 30-59 years with an LDL-C 160-189 mg/dL or 30-year risk score ≥10%, consider moderate intensity statin.
LDL-C < 100 mg/dL
and
non-HDL-C <130 mg/dL
Borderline risk: 3 to <5%Moderate-intensity statin is reasonable*.LDL-C reduction ≥30-49%
LDL-C < 100 mg/dL and
non-HDL-C <130 mg/dL
Intermediate risk: 5 to <10%Moderate to high-intensity statin is recommended.

Consider high intensity for patients at higher end of risk range.
LDL-C reduction ≥30-49% (moderate intensity) or
≥50% (high intensity)
LDL-C < 100 mg/dL and
non-HDL-C <130 mg/dL
High risk: ≥ 10%High-intensity statin is recommended.

If a patient is not meeting goals after being on a maximally tolerated statin, non-statin agents such as ezetimibe, PCSK9 inhibitors, bempedoic acid, etc. can be considered.
≥50% LDL-C reduction LDL-C < 70 mg/dL and
non HDL-C <100 mg/dL

*If the need for lipid-lowering therapy is uncertain, consider any risk enhancers. CAC testing is recommended for further risk stratification and to help guide the decision to hold, postpone, or initiate therapy.

  • Biomarker recommendations:
    • Obtain at least one Lipoprotein (a) or Lp(a) level for all adults.  Lp (a) is genetically determined and independently associated with increased cardiovascular risk. So, a person with high levels of Lp(a) are considered to be at a strong, increased risk for CV events and should have more intensified LDL-C lowering.
    • Check apolipoprotein b or ApoB in certain patients. These would be patients already on lipid lowering therapy with ASCVD risk, diabetes, metabolic syndrome or elevated TGs.  ApoB reflects the total number of circulating atherogenic particles and predicts ASCVD risk more accurately than measurement of LDL-C alone.  Elevation may signify the need for more intensive therapy.  This biomarker can help tailor treatment after a patient is on max tolerated statin.
    • Check the coronary artery calcium (CAC) score in men at least 40 years of age and woman at least 45 to help guide therapy.  CAC measures the amount of calcified plaque in the coronary arteries and can help identify subclinical atherosclerosis.  Initiation or intensification of lipid-lowering therapy may be considered based on CAC findings. The intervention varies depending on what the score is.  Refer to complete guideline for more specifics.
  • Lipid-lowering therapy (LLT) is recommended for primary prevention in adults aged 40-75 years, regardless of LDL-C,  with the following high risk conditions:  diabetes, chronic kidney disease stage 3 or 4, or HIV.  For those adults > 75 years of age with these conditions, therapy can be considered in conjunction with lifestyle interventions to reduce ASCVD risk.
  • Older Adults:
    • The benefit-risk discussion should include patient priorities, functional status, comorbidities, frailty, polypharmacy, and life expectancy.
    • For adults >75 years with a life expectancy ≥2.5 years, it may be reasonable to initiate moderate-intensity statin therapy after discussing the treatment risks and benefits. If the need for LLT is uncertain, the use of CAC testing may be reasonable to guide treatment decisions.
    • In those with a life expectancy <1 year, it may be reasonable to discontinue LLT to reduce medication burden and/or adverse side effects.
  • Secondary Prevention:

For adults with ASCVD, goals and treatment depend on if the patient is NOT at very high risk, or at very high risk.  Very high risk is defined as ≥2 major ASCVD events or 1 major ASCVD event plus ≥2 high-risk conditions.

Major ASCVD events:

  • ACS (acute coronary syndrome) within the past 12 months
  • Prior myocardial infarction [other than ACS above]
  • Prior ischemic stroke
  • Symptomatic peripheral artery disease

High-risk conditions:

  • Age >65 years of age
  • Prior coronary artery revascularization
  • Current smoker
  • Diabetes
  • History of heart failure
  • Hypertension
  • LDL-C >100 mg/dL despite maximally tolerated statin plus ezetimibe
RiskTreatmentGoal
Very High RiskHigh-intensity statin.
To achieve treatment goals, in addition to max-tolerated statin:

Ezetimibe and/or PCSK9 mAb is recommended.

Consider Bempedoic acid with or without ezetimibe and/or PSCK9 mAb

For those that cannot tolerate or obtain a PSCK9 mAb, consider inclisiran
LDL-C reduction ≥50% AND
LDL-C < 55 mg/dL AND
Non-HDL-C goal <85 mg/dL
Not at Very High RiskHigh-intensity statin.

If not at treatment goals after maximally tolerated statin, can consider adding ezetimibe, PCSK9 mAb, or bempedoic acid as needed.
LDL reduction ≥50% AND
LDL-C < 70 mg/dL AND
Non-HDL-C goal <100 mg/dL
Statin IntensityDose
Low (10-29%)Fluvastatin 20-40 mg ☾

Lovastatin 20 mg ☾ 🍽
Pravastatin 10-20 mg

Simvastatin 10 mg ☾
Moderate (30-49%)Atorvastatin 10-20 mg
Fluvastatin 40 mg BID
Fluvastatin ER 80 mg

Lovastatin 40-80 mg ☾ 🍽
Pravastatin 40-80 mg
Rosuvastatin 5-10 mg

Simvastatin 20-40 mg ☾
High (≥50%)Atorvastatin 40-80 mg
Rosuvastatin 20-40 mg

Blue = hydrophilic statin (more water-soluble and has less muscle penetration, resulting in lower risk of muscle-related side effects).
☾ = take in the evening.
🍽 = Take with food.

True statin intolerance is uncommon. The benefits of statins in ASCVD risk reduction are well-documented. Clinicians should work with the patient and obtain a thorough symptom history to determine if the patient is truly intolerant. The following tool can help clinicians assess, treat, and manage these patients: Statin intolerance tool: https://tools.acc.org/LDL/StatinIntolerance/#!/.

Hypertriglyceridemia, Severe Hypercholesterolemia, and Subclinical Coronary Atherosclerosis are addressed in the full guidelines but are not discussed here.

Reference:

  1. AHA 2026 Dyslipidemia Guidelines. Link:
    2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines | Circulation
HDRX Resources Subscription QR Code

If you’d like to receive HealthDirect Clinical content via email. Use the QR code or visit the link to subscribe.

https://hdrxsvcs.com/subscribe

© 2026 HealthDirect Pharmacy Services MTK-1411  October 2026